Somerville Kurt F Has $15.27 Million Position in Johnson & Johnson $JNJ

Somerville Kurt F lessened its position in Johnson & Johnson (NYSE:JNJ) by 4.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 99,948 shares of the company’s stock after selling 4,343 shares during the quarter. Johnson & Johnson makes up about 2.6% of Somerville Kurt F’s portfolio, making the stock its 18th biggest position. Somerville Kurt F’s holdings in Johnson & Johnson were worth $15,267,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. REAP Financial Group LLC raised its position in Johnson & Johnson by 28.8% in the 2nd quarter. REAP Financial Group LLC now owns 2,176 shares of the company’s stock valued at $332,000 after buying an additional 487 shares during the last quarter. Sax Wealth Advisors LLC raised its position in Johnson & Johnson by 41.8% in the 2nd quarter. Sax Wealth Advisors LLC now owns 31,320 shares of the company’s stock valued at $4,784,000 after buying an additional 9,232 shares during the last quarter. Venturi Wealth Management LLC raised its position in Johnson & Johnson by 0.7% in the 2nd quarter. Venturi Wealth Management LLC now owns 20,026 shares of the company’s stock valued at $3,059,000 after buying an additional 137 shares during the last quarter. High Note Wealth LLC raised its position in Johnson & Johnson by 19.5% in the 2nd quarter. High Note Wealth LLC now owns 5,750 shares of the company’s stock valued at $878,000 after buying an additional 940 shares during the last quarter. Finally, SGL Investment Advisors Inc. raised its position in Johnson & Johnson by 1.3% in the 2nd quarter. SGL Investment Advisors Inc. now owns 32,749 shares of the company’s stock valued at $5,102,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. UBS Group set a $198.00 price objective on Johnson & Johnson in a report on Friday, October 3rd. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Citigroup increased their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday. Finally, The Goldman Sachs Group increased their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $191.41.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $190.97 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The stock has a 50 day moving average of $178.01 and a 200-day moving average of $163.56. The company has a market capitalization of $459.92 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.42 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.